# Nuclide record pb-212-vmt-alpha-net (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/pb-212-vmt-alpha-net/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "pb-212-vmt-alpha-net" ;
  schema:name "Lead-212 VMT-alpha-NET"@en ;
  schema:alternateName "212Pb-VMT-alpha-NET"@en, "[212Pb]VMT-α-NET"@en, "203Pb-VMT-alpha-NET (imaging analogue)"@en ;
  schema:description "A drug that targets a marker on neuroendocrine tumour cells is being tested with two versions of a radioactive metal: one lets doctors see where the tumour is on a scan, and the other delivers a strong, short-range dose of radiation to kill the tumour cells."@en ;
  schema:url <https://nuclide.cc/drugs/pb-212-vmt-alpha-net/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://perspectivetherapeutics.com/pipeline/vmt-alpha-net>, <https://clinicaltrials.gov/study/NCT05636618>, <https://www.globenewswire.com/news-release/2026/04/20/3276793/0/en/perspective-therapeutics-presents-updated-interim-data-of-212pb-vmt-%CE%B1-net-in-its-ongoing-phase-1-2a-clinical-trial-at-the-2026-aacr-annual-meeting.html>, <https://perspectivetherapeutics.com/pr/perspective-therapeutics-announces-first-patient-dosed-in-a-phase-1-study-of-212pbvmtnet-to-treat-refractory-or-relapsedneuroendocrine-tumors> ;
  nuclide:status "phase-2" ;
  nuclide:tag "alpha therapy", "SSTR2", "neuroendocrine tumours", "lead-212", "phase 1/2" ;
  nuclide:modality "alpha therapy" ;
  nuclide:related <https://nuclide.cc/drugs/alphamedix/>, <https://nuclide.cc/drugs/itm-11/>, <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/isotopes/pb-212/> ;
  nuclide:indications <https://nuclide.cc/indications/neuroendocrine/> ;
  nuclide:technologies <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/> ;
  nuclide:companies <https://nuclide.cc/companies/perspective-therapeutics/> ;
  nuclide:trials <https://nuclide.cc/trials/nct05636618/> .